Allergan price target raised to $107 from $83 at Piper Jaffray Piper Jaffray raised its price target for Allergan (AGN) shares to $107 citing the issuance of patents on Restasis. Piper believes the recent valuation expansion of shares is justified but thinks additional expansion is unlikely given the paragraph IV litigation versus Actavis (ACT). The firm reiterates a Neutral rating on Allergan.
News For AGN From The Last 14 Days
Check below for free stories on AGN the last two weeks.